Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies

[1]  H. G. van der Poel,et al.  EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2020, European urology.

[2]  J. Yaxley,et al.  68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  M. Brunelli,et al.  Incidental prostate cancer after transurethral resection of the prostate: analysis of incidence and risk factors in 458 patients. , 2020, Minerva urologica e nefrologica = The Italian journal of urology and nephrology.

[4]  D. Margolis,et al.  Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. , 2019, European urology.

[5]  B. Jereczek-Fossa,et al.  Confirmatory multiparametric magnetic resonance imaging at recruitment confers prolonged stay in active surveillance and decreases the rate of upgrading at follow-up , 2019, Prostate Cancer and Prostatic Diseases.

[6]  V. Mirone,et al.  Multiparametric Magnetic Resonance Imaging Second Opinion May Reduce the Number of Unnecessary Prostate Biopsies: Time to Improve Radiologists’ Training Program? , 2019, Clinical genitourinary cancer.

[7]  U. Capitanio,et al.  Temporal Trend in Incidental Prostate Cancer Detection at Surgery for Benign Prostatic Hyperplasia. , 2018, Urology.

[8]  V. Mirone,et al.  Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol , 2018, Urologia Internationalis.

[9]  D. Margolis,et al.  MRI‐Targeted or Standard Biopsy for Prostate‐Cancer Diagnosis , 2018, The New England journal of medicine.

[10]  R. Cohen,et al.  The Impact of Prostate Cancer Zonal Origin on Pathological Parameters at Radical Prostatectomy and Subsequent Biochemical Failure , 2017, The Journal of urology.

[11]  P. Carroll,et al.  Low-risk Prostate Cancer: Identification, Management, and Outcomes. , 2017, European urology.

[12]  M. Parmar,et al.  Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confi rmatory study , 2018 .

[13]  M. Roobol,et al.  A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment. , 2016, European urology.

[14]  L. Weissbach,et al.  Active surveillance in localized prostate cancer: comparison of incidental tumours (T1a/b) and tumours diagnosed by core needle biopsy (T1c/T2a): results from the HAROW study , 2016, BJU international.

[15]  L. Weissbach,et al.  Treatment of Incidental Prostate Cancer by Active Surveillance: Results of the HAROW Study , 2015, Urologia Internationalis.

[16]  F. Montorsi,et al.  What is the optimal definition of misclassification in patients with very low-risk prostate cancer eligible for active surveillance? Results from a multi-institutional series. , 2015, Urologic oncology.

[17]  Danny Vesprini,et al.  Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Y. Choi,et al.  Clinical Experiences of Incidental Prostate Cancer after Transurethral Resection of Prostate (TURP) According to Initial Treatment: A Study of a Korean High Volume Center , 2013, Yonsei medical journal.

[19]  R. Manecksha,et al.  Survival after incidental prostate cancer diagnosis at transurethral resection of prostate: 10-year outcomes , 2012, Irish Journal of Medical Science.

[20]  J. Fütterer,et al.  ESUR prostate MR guidelines 2012 , 2012, European Radiology.

[21]  M. Humphreys,et al.  Incidental prostate cancer revisited: Early outcomes after holmium laser enucleation of the prostate , 2011, International journal of urology : official journal of the Japanese Urological Association.

[22]  Alan W Partin,et al.  Active Surveillance Program for Prostate Cancer: An Update of the Johns Hopkins Experience , 2011 .

[23]  J. Johansson,et al.  Incidence and mortality of incidental prostate cancer: a Swedish register-based study , 2008, British Journal of Cancer.

[24]  M. Peyromaure,et al.  Predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era. , 2008, European urology.

[25]  G. Aus,et al.  Long-term follow-up of conservatively managed incidental carcinoma of the prostate A multivariate analysis of prognostic factors , 2007, Scandinavian journal of urology and nephrology.

[26]  K. Pummer,et al.  Did the rate of incidental prostate cancer change in the era of PSA testing? A retrospective study of 1127 patients. , 2003, Urology.

[27]  C. Wiggins,et al.  Incidental detection of population-based prostate cancer incidence rates through transurethral resection of the prostate. , 2002, Urologic oncology.

[28]  Y. Reinberg,et al.  Long-term followup results after expectant management of stage A1 prostatic cancer. , 1991, The Journal of urology.

[29]  P. Walsh,et al.  Prognosis of untreated stage A1 prostatic carcinoma: a study of 94 cases with extended followup. , 1986, The Journal of urology.

[30]  D. Margolis,et al.  PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. , 2016, European urology.

[31]  J. Jones,et al.  Probability of finding T1a and T1b (Incidental) prostate cancer during TURP has decreased in the PSA era , 2009, Prostate Cancer and Prostatic Diseases.